论文部分内容阅读
目的:观察体部伽玛刀联合吉非替尼治疗老年局部晚期非小细胞肺癌(NSCLC)的临床疗效及毒副反应。方法:21例老年局部晚期NSCLC患者,给予吉非替尼250mg,口服,1次/d,服药时间≥1个月,至病情进展为止;开始服药同时进行体部伽玛刀治疗,单次治疗剂量3.0～5.5Gy,总剂量50～60Gy。观察近期疗效和不良反应以及患者的生存期,与同期55例单纯伽玛刀治疗老年局部晚期NSCLC患者治疗结果相比较。结果:21例患者,CR1例,PR15例,SD3例,PD2例,近期有效率为76.19%(16/21),1年生存率47.62%(10/21),中位生存期8.1个月。主要不良反应表现为皮疹和胃肠道反应,1例发生肺间质纤维化。同期单纯伽玛刀治疗患者,近期有效率为74.55%(41/55),1年生存率为34.55%(19/55),中位生存期6.4个月。结论:体部伽玛刀联合吉非替尼是一种对老年局部晚期NSCLC比较有效的治疗方法,毒副反应较轻,临床使用安全。
Objective: To observe the clinical efficacy and side effects of body gamma knife and gefitinib in the treatment of elderly locally advanced non-small cell lung cancer (NSCLC). Methods: Twenty-one elderly patients with locally advanced NSCLC were given gefitinib 250mg orally once daily for a period of 1 month until the disease progressed. At the same time, the patients were given gamma knife treatment and single treatment The dose of 3.0 ~ 5.5Gy, the total dose of 50 ~ 60Gy. Observation of short-term efficacy and adverse reactions, as well as the survival of patients, compared with 55 cases of simple Gamma knife treatment of elderly patients with locally advanced NSCLC compared with the same period. Results: The 21 patients were CR1, PR15, SD3 and PD2. The recent effective rate was 76.19% (16/21). The 1-year survival rate was 47.62% (10/21). The median survival time was 8.1 months. The main adverse reactions showed rash and gastrointestinal reactions, pulmonary fibrosis in 1 case. The same period simple gamma knife treatment of patients, the recent effective rate was 74.55% (41/55), 1-year survival rate was 34.55% (19/55), the median survival of 6.4 months. Conclusion: Gamma knife combined with gefitinib is an effective treatment for elderly patients with locally advanced NSCLC, with less toxic side effects and safe clinical use.